READOUT · 05 / DOSE-CONTEXT
How BPC-157 dosage is expressed in the research
Animal-model figures, the routes studied, and the pharmacokinetics — read as research context, never as guidance for use.
How doses are expressed in BPC-157 research
BPC-157 dosage in the literature is expressed as a figure per unit of body weight in an animal model — not as a human dose, because no validated human dose exists. Rodent studies most commonly report doses around 10 µg/kg and 10 ng/kg, and tendon work has gone as low as 10 pg per rat [2]. The gastric-ulcer cytoprotection study used 400 ng/kg and 800 ng/kg in rats [4]. Human pilot data are minimal and use whole-milligram amounts: a 2-person IV safety pilot infused 10 mg then 20 mg [9], and an interstitial-cystitis pilot used a single 10 mg intravesical dose [11].
These are the figures the studies report, logged for the record. This page does not convert them into a human protocol, does not recommend an amount, frequency or duration, and does not describe how to prepare or administer anything. The numbers describe experiments; they are not instructions.
BPC-157 half-life and pharmacokinetics
BPC-157 half-life is short. The first formal PK/ADME study (2022, rats and beagle dogs) reported an elimination half-life of under 30 minutes for the prototype peptide, with linear pharmacokinetics across doses [5]. Intramuscular bioavailability was around 14-19% in rats and 45-51% in dogs; the peptide broke down rapidly into small fragments entering normal amino-acid metabolism, with excretion via urine and bile [5].
A sub-30-minute half-life is consistent with the repeated daily dosing used throughout the animal literature, and it is one reason the research record does not describe a single-dose "works immediately" effect. Human pharmacokinetics, beyond the tiny safety pilot, are not established [5][9].
Routes studied (including injection)
BPC-157 injection routes dominate the animal work. The most common rodent route is intraperitoneal, followed by intramuscular; the PK study characterized intravenous and intramuscular delivery [5]. The gastric-ulcer study compared intramuscular against intragastric and found intramuscular outperformed it [4]. Human pilots used intravenous infusion (the 2-person safety study) [9], intravesical instillation (the interstitial-cystitis pilot) [11], and intra-articular injection (the knee-pain case series).
The spread of routes — intraperitoneal, intramuscular, intragastric, local/intra-lesional, intravenous, intravesical, intra-articular — reflects how broadly the peptide has been probed in models, not an endorsement of any route in people. Each route appears here as a fact about study design.
Oral and peroral BPC-157 in studies
BPC-157 oral administration is studied, and it traces back to the name. BPC-157 is called a stable gastric pentadecapeptide because it is reported to be stable in human gastric juice, which is what underlies interest in oral and peroral delivery [1]. Animal studies do use peroral and intragastric routes and report effects [4].
The honest limit: despite the gastric-stability property, formal human oral pharmacokinetics are not established [1]. Reported gastric-juice stability is a molecular observation, not a demonstration that oral BPC-157 produces a defined, measured effect in people. Storage and reconstitution practices discussed online are research-handling context, not validated clinical protocols.
How long should I stay on BPC-157?
There is no validated human protocol and therefore no duration to cite. Study durations are defined per experiment in animals, not as guidance for people. The literature provides no human duration figure, and this site does not supply one.
Can BPC-157 be taken orally?
BPC-157 is termed a stable gastric pentadecapeptide because it is reported stable in gastric juice, and peroral routes are used in animal studies [1]. However, formal human oral pharmacokinetics are not established, so oral activity in people is not confirmed by the research.
Does oral BPC-157 work?
Animal studies use peroral and intragastric routes and report effects [4], but there is no validated human oral pharmacokinetic or efficacy data confirming oral activity in people. The gastric-stability property is suggestive, not a demonstration of oral efficacy in humans.